Scleroza multiplă și viața cu aceasta.
71 de articoleThis is a corrigendum (correction notice) for a peer-reviewed study investigating biomarkers that predict treatment response to ocrelizumab in patients with relapsing-remitting multiple sclerosis. The notice addresses corrections to the original published article.
This cross-sectional study examined lipid profiles and lipoprotein particle characteristics in 203 healthy controls, 221 patients with relapsing-remitting MS, and 126 with progressive MS, using advanced NMR profiling and immunoassay methods. Results showed similar dyslipidemia frequency across groups but progressive MS exhibited altered triglyceride-rich and LDL particle concentrations, with lower disability scores associated with higher HDL particle levels.
This research investigates the relationship between hippocampal antibodies and cognitive impairment in multiple sclerosis patients. The study examines potential autoimmune mechanisms underlying cognitive dysfunction, a common but often under-recognized MS symptom.
This study of 1542 MS patients and 700 controls found that people with MS have lower odds of seasonal allergies compared to unaffected controls, with variations by MS disease course. Genetic analysis revealed that MS-specific genetic risk factors (HLA-DRB1*15:01 and non-MHC genetic risk scores) are associated with differential susceptibility to allergic conditions in MS patients.
This commentary discusses a UK study of 364 multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (aHSCT), showing positive responses across all MS types, with particularly high response rates in relapsing-remitting forms. The authors argue that aHSCT represents a powerful, effective, and safer therapeutic option for MS patients compared to conventional disease-modifying treatments.
A prospective study of 61 MS patients found that four months of fingolimod treatment did not produce significant changes in anxiety or depression scores compared to baseline. At baseline, MS relapses and prior medication use were associated with depression, while recent adverse life events correlated with anxiety.
This clinical study of 149 MS patients found that 16% developed polyneuropathy (PNP), with highest prevalence (35.7%) in secondary progressive MS, and identified male gender and higher neuropathy scores as risk factors. Nerve conduction studies confirmed demyelinating characteristics of PNP in MS, suggesting peripheral nervous system involvement despite MS primarily affecting the central nervous system.
This case-control study applied Bayesian computational modeling to examine how patients with relapsing-remitting MS process temporal information, revealing increased bias toward prior expectations over sensory information compared to healthy controls. The findings suggest that greater sensory measurement noise in MS patients drives this cognitive dysfunction, and unlike healthy aging, age-related changes in reliance on prior expectations are absent in MS patients.
This review examines autologous hematopoietic stem cell transplantation (AHSCT) as an emerging therapeutic option for patients with relapsing-remitting MS who are resistant to disease-modifying therapies, demonstrating sustained remission and lower relapse rates compared to conventional treatments. While AHSCT shows promise in preventing progression and improving neurological outcomes, results are mixed in progressive MS cases, and further research is needed to identify optimal patient selection and transplant protocols.
This study demonstrates that people with MS show measurable deficits in both perceptual timing (beat detection) and motor timing (finger-tapping consistency) compared to normative data, attributed to basal ganglia microstructural damage. These timing impairments correlate significantly with disease progression and fatigue severity, suggesting temporal processing measures could serve as objective biomarkers for MS disease activity.
Multiple sclerosis is a chronic autoimmune demyelinating disorder of the central nervous system that typically presents between ages 20-40, with higher prevalence in women and Northern European/North American populations. Current therapeutic approaches include disease-modifying immunomodulatory agents (interferons, glatiramer acetate, monoclonal antibodies, fumarates, and others) and symptomatic treatments to manage disease progression and disability.